Starboard Value, a prominent activist investor, has reportedly acquired a significant stake in Kenvue Inc., the company behind popular consumer brands like Tylenol and Listerine. The move signals potential changes for Kenvue, which has faced stock underperformance since its spin-off from Johnson & Johnson last year. Starboard’s CEO, Jeff Smith, is expected to outline his plans for Kenvue at an upcoming activist investing conference.
Results for: Kenvue
Kenvue Inc. (KVUE), the parent company of popular brands like Listerine, Mylanta, and Tylenol, is showing strong bullish signals. The stock is approaching a Golden Cross, a technical indicator suggesting potential for a significant price increase. A recent legal victory regarding Tylenol ‘Rapid Release’ gelcaps further strengthens the company’s position.
Kenvue, the maker of Tylenol, has successfully defended itself against a lawsuit alleging misleading marketing of ‘Rapid Release’ gelcaps. A federal judge ruled that the lawsuit was preempted by FDA regulations, finding that the agency does not recognize the term ‘rapid release’ for acetaminophen products.